Skip to main content
Clinical Trials/EUCTR2020-005653-24-ES
EUCTR2020-005653-24-ES
Active, Not Recruiting
Phase 1

Effectiveness of botulinum toxin infiltration in spasticity of the 1st toe in patients with neurological pathology

Clínica Integral del pie-Ana Sans0 sites120 target enrollmentJune 14, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
The application of Botox is described in the technical sheet for spasticity and has already been applied to the foot. This is how we speak of a phase IV clinical trial, with a low level of intervention.
Sponsor
Clínica Integral del pie-Ana Sans
Enrollment
120
Status
Active, Not Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 14, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Clínica Integral del pie-Ana Sans

Eligibility Criteria

Inclusion Criteria

  • Neurological patients aged 18 to 80 years
  • Patients with stroke, parkinson's or multiple sclerosis, who present spasticity of the 1st toe.
  • Spasticity of the 1st toe, pain and gait instability.
  • Hyperextension of the 1st finger, causing inability to put on shoes, in neurological patients.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 60
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 60

Exclusion Criteria

  • Skin ulcers
  • In pregnancy and lactation the use is contraindicated.
  • Minor patients and those patients who do not have the authorization of a family member or guardian.
  • Individuals with known hypersensitivity to botulinum toxin type A or to any of the excipients of the formulation.
  • In case of infection at the proposed injection site (s).
  • Eaton Lambert Syndrome patients.
  • Patients with severe dysphagia or respiratory compromise.
  • Patients with myasthenia gravis.

Outcomes

Primary Outcomes

Not specified

Similar Trials